Geron - GERN Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Geron in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GERN shares.
View GERN analyst ratings or view top-rated stocks.

4 analysts have issued 12-month price targets for Geron's stock. Their GERN share price forecasts range from $3.00 to $7.00. On average, they expect the company's share price to reach $4.50 in the next twelve months. This suggests a possible upside of 96.5% from the stock's current price.
View analysts price targets for GERN or view top-rated stocks among Wall Street analysts.

Geron's stock was trading at $1.22 at the beginning of 2022. Since then, GERN shares have increased by 87.7% and is now trading at $2.29.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our GERN earnings forecast.

Geron Co. (NASDAQ:GERN) posted its earnings results on Thursday, August, 11th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.02. Geron had a negative trailing twelve-month return on equity of 90.38% and a negative net margin of 8,693.61%. During the same quarter in the prior year, the company earned ($0.09) earnings per share.

5 employees have rated Geron Chief Executive Officer John A. Scarlett on Glassdoor.com. John A. Scarlett has an approval rating of 82% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Geron investors own include Novavax (NVAX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Rigel Pharmaceuticals (RIGL), Chesapeake Energy (CHKAQ), OrganiGram (OGI), SCYNEXIS (SCYX) and Bionano Genomics (BNGO).

Geron trades on the NASDAQ under the ticker symbol "GERN."

Geron's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Bioimpact Capital LLC (2.23%), Northern Trust Corp (0.96%), Millennium Management LLC (0.53%), Healthcare of Ontario Pension Plan Trust Fund (0.21%), Swiss National Bank (0.21%) and Goldman Sachs Group Inc. (0.20%).
View institutional ownership trends.

Shares of GERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GERN stock can currently be purchased for approximately $2.29.

Geron (NASDAQ:GERN) has a market capitalization of $865.21 million and generates $1.39 million in revenue each year. The biopharmaceutical company earns $-116,110,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis.

Geron's mailing address is 919 EAST HILLSDALE BOULEVARD SUITE 250, FOSTER CITY CA, 94404. The official website for the company is www.geron.com. The biopharmaceutical company can be reached via phone at (650) 473-7700, via email at investor@geron.com, or via fax at 650-473-7750.